Exhibit 99.1 INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights • BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papillomatosis (RRP) • Planning initiation of confirmatory trial for INO-3107 based on FDA feedback • Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM (toripalimab-tpzi) as a potential treatment for oropharyngeal ...